Shares of Niagen Bioscience (NAGE) slid 9.5% to $2.28 after the dietary-supplement and longevity-science company disclosed a third quarter that fell short on both revenue and earnings, raising pointed questions about whether its core business is shrinking faster than management can adapt. Niagen Bioscience's Revenue Reversal Wipes Out a Year of Momentum — Is a $185 Million Valuation Enough Cushion or a Value Trap?
Shares of Niagen Bioscience tumbled 9.5% to $2.28 after the supplement and healthy-aging company posted a third quarter that shattered the growth story it had been building for three years. Q3 net sales came in at $27.2 million, well below the $32.1 million analyst consensus, alongside a net loss of $1.17 million. The stock now trades 71% below its 52-week high of $7.95, and the question for shareholders is whether the business is merely cooling off or genuinely shrinking.
• The Miss Was Far Deeper Than Wall Street Feared
Analysts had already braced for a decline, forecasting a $0.01 per-share loss and revenue of $30.15 million, down about 11% year over year. The actual 20% revenue drop to $27.2 million blew past even the bearish estimates, leaving sales roughly $5 million short of the consensus. That is a dramatic swing from Q3 2025, when revenue grew 33% year over year to $34 million. Two consecutive quarters of revenue declines — Q2 revenue fell about 4.3% — suggest this is a trend, not a blip.
• The Ingredient Business Is Dragging Down the Whole Company
Management expects direct website revenue to grow 15% to 20% in 2026, but the ingredient business — which sells raw materials to partners — is expected to decline due to lower volume from key partners.
Selling and marketing costs already climbed to 34% of sales in Q2 while ingredient revenue suffered from weaker partner orders and intensifying competition from NMN , a rival compound. When one revenue stream grows and a bigger one shrinks, the net effect is contraction.
• Thin Profits Have Evaporated Into Losses
In Q2, net income fell roughly 73% year over year yet remained positive. Now the company has tipped into a loss. Adjusted EBITDA of just $0.5 million is barely above breakeven, signaling that heavier marketing spending is not translating into enough sales to cover costs. The $69.5 million cash balance and $2.6 million in operating cash flow provide a financial safety net — but cash on hand is not a growth strategy.
• A Cheap Stock Price Does Not Mean a Cheap Stock
At a market capitalization of roughly $185 million and trailing earnings of about $0.19 per share, the stock carries a price-to-earnings ratio around 12. That looks inexpensive — until you consider that earnings are evaporating quarter by quarter. Shares have lost about 44.5% year to date versus the S&P 500's 11% gain , and without a clear catalyst to reverse the ingredient-business slide, the discount may simply reflect reality.